Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.11, $0.34 worse than the analyst estimate of $1.45. Revenue for the quarter came in at $5.1 billion versus the consensus estimate of $5.31 billion.

GUIDANCE:

Gilead Sciences sees FY2020 EPS of $6.25-$7.65, versus the consensus of $6.71. Gilead Sciences sees FY2020 revenue of $23-25 billion, versus the consensus of $23.44 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.